两样本孟德尔随机化分析肠道菌群与肝外胆管癌的因果关系

doi:10.6040/j.issn.1671-7554.0.2024.0686

摘要/Abstract

摘要： 目的采用两样本孟德尔随机化(Mendelian randomization, MR)方法评估肠道菌群与肝外胆管癌之间的因果关系。方法从MiBioGen数据库下载人类肠道菌群的全基因组关联研究(genome-wide association study, GWAS)数据作为暴露因素,从GWAS Catalog官网获取肝外胆管癌GWAS数据作为结局,使用随机效应逆方差加权法、加权中位数法、MR-Egger回归、简单模式和加权模式等5种方法进行MR分析,探索肠道菌群与肝外胆管癌发病风险之间的因果关系,并对MR结果进行敏感性分析、异质性检验、多效性检验,评估结果的可靠性和准确性。结果最终筛选出55个与肠道菌群有关的工具变量。MR结果显示颤螺菌属(OR=6.705,95%CI:1.612~27.890,P=0.009)、普氏菌属7(OR=2.565,95%CI:1.108~5.940,P=0.028)和Family_XIII_AD3011_group(OR=5.513,95%CI:1.186~25.620,P=0.029)与肝外胆管癌之间呈正向因果关系;氨基酸球菌科(OR=0.113,95%CI:0.026~0.500,P=0.004)、乳酸杆菌科(OR=0.349,95%CI:0.132~0.924,P=0.034)和丁酸弧菌属(OR=0.493,95%CI:0.252~0.963,P=0.039)与肝外胆管癌之间呈负向因果关系,同时MR Egger、加权中位数法、简单模式和加权模式与逆方差加权法的结果方向一致。敏感性分析结果提示不存在水平多效性及异质性,MR结果可靠。结论颤螺菌属、普氏菌属7、Family_XIII_AD3011_group、氨基酸球菌科、乳酸杆菌科和丁酸弧菌属与肝外胆管癌之间具有潜在因果关系。

关键词: 肠道菌群, 肝外胆管癌, 孟德尔随机化, 全基因组关联研究, 因果关系

Abstract: Objective To evaluate the causal relationship between gut microbiota and extrahepatic cholangiocarcinoma(ECC)by using two-sample Mendelian randomization(MR)analysis. Methods Genome-wide association study(GWAS)data of human gut microbiota were obtained from the official website of MiBioGen Alliance as exposure factors, and GWAS data of ECC were obtained from the official website of GWAS Catalog as the outcome. Five methods, including random effect inverse variance weighting, weighted median, MR-Egger regression, simple model and weighted model, were used to conduct two-sample MR to explore the causal relationship between gut microbiota and the risk of ECC. Sensitivity analysis, heterogeneity test and pleiotropy test were also conducted to evaluate the reliability and accuracy of the results. Results Finally, 55 instrumental variables related to gut microbiota were selected. MR results showed that the Oscillospira(OR=6.705, 95%CI: 1.612-27.890, P=0.009), Prevotella 7(OR=2.565, 95%CI: 1.108-5.940, P=0.028) and Family_XIII_AD3011_group(OR=5.513, 95%CI: 1.186-25.620, P=0.029)were positively correlated with ECC. There was a negative causal relationship between Acidaminococcaceae(OR=0.113, 95%CI: 0.026-0.500, P=0.004), Lactobacillaceae(OR=0.349, 95%CI: 0.132-0.924, P=0.034), Butyrivibrio(OR=0.493, 95%CI: 0.252-0.963, P=0.039)and ECC. The direction of MR Egger, weighted median method, simple model and weighted model was consistent with inverse variance weighted method. Sensitivity analysis showed no horizontal pleiotropy and heterogeneity, and MR results were reliable. Conclusion There is a potential causal relationship between Oscillospira, Prevotella 7, Family_XIII_AD3011_group, Acidaminococcaceae, Lactobacillaceae, Butyrivibrio and ECC.

Key words: Gut microbiota, Extrahepatic cholangiocarcinoma, Mendelian randomization, Genome-wide association study, Causal relationship

中图分类号:

R735.7

王小磊,方骏,王安,朱武晖,史光军. 两样本孟德尔随机化分析肠道菌群与肝外胆管癌的因果关系[J]. 山东大学学报 (医学版), 2025, 63(4): 44-50.

WANG Xiaolei, FANG Jun, WANG An, ZHU Wuhui, SHI Guangjun. Two-sample Mendelian randomization of the relationship between gut microbiota and the risk of extrahepatic cholangiocarcinoma[J]. Journal of Shandong University (Health Sciences), 2025, 63(4): 44-50.

参考文献

[1] 刘洋, 阮祥, 段安琪, 等. 《英国胃肠病学会胆管癌诊治指南(2023版)》更新解读[J]. 中国实用外科杂志, 2024, 44(3): 292-299. LIU Yang, RUAN Xiang, DUAN Anqi, et al. Update and interpretation of British gastroenterology association guidelines for diagnosis and treatment of cholangiocarcinoma(2023 edition)[J]. Chinese Journal of Practical Surgery, 2024, 44(3): 292-299.
[2] Vithayathil M, Khan SA. Current epidemiology of cholangiocarcinoma in western countries[J]. J Hepatol, 2022, 77(6): 1690-1698.
[3] Benson AB, DAngelica MI, Abrams T, et al. NCCN guidelines^® insights: biliary tract cancers, version 2.2023[J]. J Natl Compr Canc Netw, 2023, 21(7): 694-704.
[4] Brindley PJ, Bachini M, Ilyas SI, et al. Cholangiocarcinoma[J]. Nat Rev Dis Primers, 2021, 7(1): 65. doi:10.1038/s41572-021-00300-2
[5] 彭彬彬,周智. 胆管癌危险因素研究进展[J]. 临床医学进展, 2023, 13(3): 4025-4031.
[6] 龙祯, 孔棣. 肝外胆管癌致病因素的研究进展[J]. 江西中医药, 2017, 48(8): 72-75. LONG Zhen, KONG Di. Research progress on pathogenic factors of extrahepatic cholangiocarcinoma[J]. Jiangxi Journal of Traditional Chinese Medicine, 2017, 48(8): 72-75.
[7] Qiu P, Ishimoto T, Fu LF, et al. The gut microbiota in inflammatory bowel disease[J]. Front Cell Infect Microbiol, 2022, 12: 733992. doi:10.3389/fcimb.2022.733992
[8] Zhang LL, Chu JJ, Hao WH, et al. Gut microbiota and type 2 diabetes mellitus: association, mechanism, and translational applications[J]. Mediators Inflamm, 2021, 2021: 5110276. doi:10.1155/2021/5110276
[9] Pant A, Maiti TK, Mahajan D, et al. Human gut microbiota and drug metabolism[J]. Microb Ecol, 2023, 86(1): 97-111.
[10] Campbell C, Kandalgaonkar MR, Golonka RM, et al. Crosstalk between gut microbiota and host immunity: impact on inflammation and immunotherapy[J]. Biomedicines, 2023, 11(2): 294. doi:10.3390/biomedicines11020294
[11] Quaglio AEV, Grillo TG, De Oliveira ECS, et al. Gut microbiota, inflammatory bowel disease and colorectal cancer[J]. World J Gastroenterol, 2022, 28(30): 4053-4060.
[12] Cai J, Sun LL, Gonzalez FJ. Gut microbiota-derived bile acids in intestinal immunity, inflammation, and tumorigenesis[J]. Cell Host Microbe, 2022, 30(3): 289-300.
[13] Birney E. Mendelian randomization[J]. Cold Spring Harb Perspect Med, 2022, 12(4): a041302. doi:10.1101/cshperspect.a041302
[14] 王莉娜, Zhang Zuofeng. 孟德尔随机化法在因果推断中的应用[J]. 中华流行病学杂志, 2017, 38(4): 547-552. WANG Lina, ZHANG Zuofeng. Mendelian randomization approach, used for causal inferences[J]. Chinese Journal of Epidemiology, 2017, 38(4): 547-552.
[15] Skrivankova VW, Richmond RC, Woolf BAR, et al. Strengthening the reporting of observational studies in epidemiology using mendelian randomization: the STROBE-MR statement[J]. JAMA, 2021, 326(16): 1614-1621.
[16] Zheng ZM, Hou XX, Bian ZX, et al. Gut microbiota and colorectal cancer metastasis[J]. Cancer Lett, 2023, 555: 216039. doi:10.1016/j.canlet.2022.216039
[17] Matsushita M, Fujita K, Hayashi T, et al. Gut microbiota-derived short-chain fatty acids promote prostate cancer growth via IGF1 signaling[J]. Cancer Res, 2021, 81(15): 4014-4026.
[18] Long YW, Tang LH, Zhou YY, et al. Causal relationship between gut microbiota and cancers: a two-sample Mendelian randomisation study[J]. BMC Med, 2023, 21(1): 66. doi:10.1186/s12916-023-02761-6
[19] Ai DM, Xing YL, Zhang QC, et al. Joint analysis of microbial and immune cell abundance in liver cancer tissue using a gene expression profile deconvolution algorithm combined with foreign read remapping[J]. Front Immunol, 2022, 13: 853213. doi:10.3389/fimmu.2022.853213
[20] Guo H, Yu LL, Tian FW, et al. The potential therapeutic role of Lactobacillaceae rhamnosus for treatment of inflammatory bowel disease[J]. Foods, 2023, 12(4): 692. doi:10.3390/foods12040692
[21] Stoeva MK, Garcia-So J, Justice N, et al. Butyrate-producing human gut symbiont, Clostridium butyricum, and its role in health and disease[J]. Gut Microbes, 2021, 13(1): 1-28.
[22] Jia W, Xie GX, Jia WP. Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis[J]. Nat Rev Gastroenterol Hepatol, 2018, 15(2): 111-128.
[23] Collins SL, Stine JG, Bisanz JE, et al. Bile acids and the gut microbiota: metabolic interactions and impacts on disease[J]. Nat Rev Microbiol, 2023, 21(4): 236-247.
[24] Song YC, Wang XC, Lu XH, et al. Exposure to microcystin-LR promotes colorectal cancer progression by altering gut microbiota and associated metabolites in APC^min/+ mice[J]. Toxins, 2024, 16(5): 212. doi:10.3390/toxins16050212
[25] Yang JP, Li YN, Wen ZQ, et al. Oscillospira-a candidate for the next-generation probiotics[J]. Gut Microbes, 2021, 13(1): 1987783. doi:10.1080/19490976.2021.1987783
[26] Wu J, Xu S, Xiang CJ, et al. Tongue coating microbiota community and risk effect on gastric cancer[J]. J Cancer, 2018, 9(21): 4039-4048.
[27] Haneishi Y, Furuya Y, Hasegawa M, et al. Inflammatory bowel diseases and gut microbiota[J]. Int J Mol Sci, 2023, 24(4): 3817. doi:10.3390/ijms24043817

相关文章 15

[1]	徐晶晶,王新起,张洋,许旺旺,高进. P2X7受体抑制剂对青春期创伤后应激障碍大鼠行为及肠道菌群的影响[J]. 山东大学学报 (医学版), 2025, 63(4): 1-9.
[2]	李建锋,张展,丁新华,高奋堂,何勤利,谢萍. 欧洲人群饮食因素与认知功能障碍关系的孟德尔随机化分析[J]. 山东大学学报 (医学版), 2025, 63(4): 36-43.
[3]	杨慧,苏士晶,李芬. 基于双向孟德尔随机化法探讨组织蛋白酶与衰弱的因果关联[J]. 山东大学学报 (医学版), 2025, 63(2): 67-76.
[4]	常宇,胡云峰,王会丰,郭静,张跳,郝雅琴,刘雨. 阑尾切除术与结直肠癌发病风险关联的孟德尔随机化研究[J]. 山东大学学报 (医学版), 2025, 63(2): 77-83.
[5]	袁宗怀,潘广晔,迟曰梅,安传国,张永刚. 孟德尔随机化分析低级别浆液性卵巢癌与乳腺癌的因果关系[J]. 山东大学学报 (医学版), 2025, 63(1): 99-107.
[6]	刘绍庭,张薇薇,冉茜,王建. 食品乳化剂与肠道健康[J]. 山东大学学报 (医学版), 2024, 62(8): 18-26.
[7]	张展,李建锋,李燕玲,王博雯,昂文成林龙珠,王鑫,张小明,谢萍. 饮食因素与子痫前期因果关系的孟德尔随机化分析[J]. 山东大学学报 (医学版), 2024, 62(8): 59-66.
[8]	冯悦,俞一凡,吴思佳,李洪凯,薛付忠. 内脏脂肪组织与肺部疾病的孟德尔随机化研究[J]. 山东大学学报 (医学版), 2024, 62(7): 48-55.
[9]	吴彤,杨晶玉,林盪,徐婉茹,曾宇鋆. 基于孟德尔随机化方法探讨脂质和降脂药物与慢性阻塞性肺病的遗传关联[J]. 山东大学学报 (医学版), 2024, 62(5): 54-63.
[10]	吴飞,李清丽,肖振卫. 孟德尔随机化探究细胞因子与慢性肾脏病的因果关系[J]. 山东大学学报 (医学版), 2024, 62(11): 85-95.
[11]	陈泰宇,唐学贵,唐诗宇,张智彬,陈思敏,李敏,庞峻. 白头翁汤对短肠综合征小鼠肠道功能的影响[J]. 山东大学学报 (医学版), 2023, 61(9): 29-37.
[12]	张娜娜,赵一鸣,刘新敏. 基于两样本孟德尔随机化探索子宫肌瘤与乳腺癌的因果关系[J]. 山东大学学报 (医学版), 2023, 61(8): 86-93.
[13]	张天鑫,张婷,黄鑫,韩佳沂,王淑康. 氨基酸与2型糖尿病因果关系的孟德尔随机化分析[J]. 山东大学学报 (医学版), 2023, 61(5): 102-107.
[14]	常鑫,刘世佳,韩璐. 服用阿司匹林与子宫内膜癌发病风险的孟德尔随机化关系[J]. 山东大学学报 (医学版), 2023, 61(10): 58-62.
[15]	张凯,司书成,李吉庆,刘晓雯,赵英琪,薛付忠. 睡眠性状与肠易激综合征的孟德尔随机化研究[J]. 山东大学学报 (医学版), 2022, 60(8): 109-114.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed